argenex SE (NASDAQ:ARGX) Given Average Rating of "Buy" by Brokerages

Shares of argenex SE (NASDAQ:ARGX - Get Free Report) have been assigned an average rating of "Buy" from the twenty-one ratings firms that are currently covering the firm, Marketbeat.com reports. Nineteen analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $728.06.

Several equities research analysts have weighed in on the company. HC Wainwright reiterated a "buy" rating and issued a $720.00 target price on shares of argenex in a report on Tuesday, July 1st. Baird R W raised argenex from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 13th. Citigroup reissued a "buy" rating on shares of argenex in a report on Wednesday, May 21st. Deutsche Bank Aktiengesellschaft raised argenex from a "hold" rating to a "buy" rating in a report on Tuesday. Finally, Guggenheim lowered their price target on argenex from $1,100.00 to $1,065.00 and set a "buy" rating on the stock in a research report on Friday, May 9th.

Hedge Funds Weigh In On argenex

Large investors have recently modified their holdings of the business. Point72 Europe London LLP acquired a new stake in argenex during the 4th quarter valued at $5,839,000. Ameriprise Financial Inc. lifted its stake in shares of argenex by 10.0% during the 4th quarter. Ameriprise Financial Inc. now owns 7,013 shares of the company's stock worth $4,313,000 after purchasing an additional 639 shares during the period. Jones Financial Companies Lllp lifted its stake in shares of argenex by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock worth $41,000 after purchasing an additional 61 shares during the period. PNC Financial Services Group Inc. lifted its stake in shares of argenex by 13.3% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,538 shares of the company's stock worth $946,000 after purchasing an additional 181 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of argenex by 21.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 4,214 shares of the company's stock worth $2,592,000 after purchasing an additional 755 shares during the period. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenex Stock Up 1.5%

ARGX stock opened at $563.31 on Friday. The business's 50-day moving average price is $569.33 and its 200-day moving average price is $602.50. argenex has a twelve month low of $457.42 and a twelve month high of $678.21. The stock has a market cap of $34.40 billion, a P/E ratio of 34.75, a PEG ratio of 1.02 and a beta of 0.37.

argenex (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.32 by $0.26. The business had revenue of $1.35 billion for the quarter, compared to analysts' expectations of $748.34 million. argenex had a return on equity of 16.15% and a net margin of 40.20%. On average, equities research analysts expect that argenex will post 3.13 earnings per share for the current fiscal year.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.